Advertisement
Advertisement
U.S. Markets open in 3 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4200-0.1300 (-8.39%)
At close: 04:00PM EST
1.4000 -0.02 (-1.41%)
After hours: 05:14PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5500
Open1.5300
Bid0.0000 x 1000
Ask0.0000 x 1100
Day's Range1.4000 - 1.5300
52 Week Range1.0300 - 5.8500
Volume134,389
Avg. Volume521,752
Market Cap12.42M
Beta (5Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)-1.7040
Earnings DateNov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • ACCESSWIRE

    Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

    * Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies * Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placement * Continued royalty stream growth through license agreement with PolyXen® platform technologyFRAMINGHAM, MA / ACCESSWIRE / November 12, 2021 / Xenetic Biosciences, Inc.

  • Zacks

    Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for

    Xenetic Biosciences (XBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

    Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCARTFRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the United States Patent and Trademark Office (USPTO) has issued Xenetic a Notice of Allo

Advertisement
Advertisement